Risk assessment in human immunodeficiency virus-associated acute myeloid leukemia

Michael W. Evans, Anthony D. Sung, Ivana Gojo, Michael Tidwell, Jacqueline Greer, Mark J Levis, Judith Karp, Maria R. Baer

Research output: Contribution to journalArticle

Abstract

CD4 count ≤200×10 6 cells/L has been identified as a predictor of short survival in HIV-associated acute myeloid leukemia (HIV-AML), but karyotype, which is the best predictor of survival in AML, has not been evaluated in HIV-AML patients. A retrospective cohort of 31 patients was created from 9 local cases and 22 published cases. HIV-AML karyotypes were heterogeneous and were similar in distribution to those in HIV-negative AML. Among intensively treated patients, most achieved complete remission, but succumbed to infectious complications, mostly non-opportunistic, during consolidation therapy. Median survival for intensively-treated patients with CD4 counts ≤200×10 6 cells/L was 8.5 months, compared to 48 months for those with >200×10 6 CD4 cells/L (p=0.03). In contrast, AML karyotype did not predict survival (p=0.43), albeit with small numbers in each karyotype group. Thus, CD4 count is a strong predictor of short survival in HIV-AML patients regardless of karyotype. Studies evaluating innovative strategies for infection prophylaxis and for improving immune reconstitution are needed.

Original languageEnglish (US)
Pages (from-to)660-664
Number of pages5
JournalLeukemia and Lymphoma
Volume53
Issue number4
DOIs
StatePublished - Apr 2012

Fingerprint

Karyotype
Acute Myeloid Leukemia
HIV
CD4 Lymphocyte Count
Survival
Infection
Therapeutics

Keywords

  • Acquired immunodeficiency syndrome
  • Acute myeloid leukemia
  • Human immunodeficiency virus
  • Risk assessment

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Risk assessment in human immunodeficiency virus-associated acute myeloid leukemia. / Evans, Michael W.; Sung, Anthony D.; Gojo, Ivana; Tidwell, Michael; Greer, Jacqueline; Levis, Mark J; Karp, Judith; Baer, Maria R.

In: Leukemia and Lymphoma, Vol. 53, No. 4, 04.2012, p. 660-664.

Research output: Contribution to journalArticle

Evans, Michael W. ; Sung, Anthony D. ; Gojo, Ivana ; Tidwell, Michael ; Greer, Jacqueline ; Levis, Mark J ; Karp, Judith ; Baer, Maria R. / Risk assessment in human immunodeficiency virus-associated acute myeloid leukemia. In: Leukemia and Lymphoma. 2012 ; Vol. 53, No. 4. pp. 660-664.
@article{fbac0f090dd748169d592b8c3e64fa11,
title = "Risk assessment in human immunodeficiency virus-associated acute myeloid leukemia",
abstract = "CD4 count ≤200×10 6 cells/L has been identified as a predictor of short survival in HIV-associated acute myeloid leukemia (HIV-AML), but karyotype, which is the best predictor of survival in AML, has not been evaluated in HIV-AML patients. A retrospective cohort of 31 patients was created from 9 local cases and 22 published cases. HIV-AML karyotypes were heterogeneous and were similar in distribution to those in HIV-negative AML. Among intensively treated patients, most achieved complete remission, but succumbed to infectious complications, mostly non-opportunistic, during consolidation therapy. Median survival for intensively-treated patients with CD4 counts ≤200×10 6 cells/L was 8.5 months, compared to 48 months for those with >200×10 6 CD4 cells/L (p=0.03). In contrast, AML karyotype did not predict survival (p=0.43), albeit with small numbers in each karyotype group. Thus, CD4 count is a strong predictor of short survival in HIV-AML patients regardless of karyotype. Studies evaluating innovative strategies for infection prophylaxis and for improving immune reconstitution are needed.",
keywords = "Acquired immunodeficiency syndrome, Acute myeloid leukemia, Human immunodeficiency virus, Risk assessment",
author = "Evans, {Michael W.} and Sung, {Anthony D.} and Ivana Gojo and Michael Tidwell and Jacqueline Greer and Levis, {Mark J} and Judith Karp and Baer, {Maria R.}",
year = "2012",
month = "4",
doi = "10.3109/10428194.2011.624228",
language = "English (US)",
volume = "53",
pages = "660--664",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Risk assessment in human immunodeficiency virus-associated acute myeloid leukemia

AU - Evans, Michael W.

AU - Sung, Anthony D.

AU - Gojo, Ivana

AU - Tidwell, Michael

AU - Greer, Jacqueline

AU - Levis, Mark J

AU - Karp, Judith

AU - Baer, Maria R.

PY - 2012/4

Y1 - 2012/4

N2 - CD4 count ≤200×10 6 cells/L has been identified as a predictor of short survival in HIV-associated acute myeloid leukemia (HIV-AML), but karyotype, which is the best predictor of survival in AML, has not been evaluated in HIV-AML patients. A retrospective cohort of 31 patients was created from 9 local cases and 22 published cases. HIV-AML karyotypes were heterogeneous and were similar in distribution to those in HIV-negative AML. Among intensively treated patients, most achieved complete remission, but succumbed to infectious complications, mostly non-opportunistic, during consolidation therapy. Median survival for intensively-treated patients with CD4 counts ≤200×10 6 cells/L was 8.5 months, compared to 48 months for those with >200×10 6 CD4 cells/L (p=0.03). In contrast, AML karyotype did not predict survival (p=0.43), albeit with small numbers in each karyotype group. Thus, CD4 count is a strong predictor of short survival in HIV-AML patients regardless of karyotype. Studies evaluating innovative strategies for infection prophylaxis and for improving immune reconstitution are needed.

AB - CD4 count ≤200×10 6 cells/L has been identified as a predictor of short survival in HIV-associated acute myeloid leukemia (HIV-AML), but karyotype, which is the best predictor of survival in AML, has not been evaluated in HIV-AML patients. A retrospective cohort of 31 patients was created from 9 local cases and 22 published cases. HIV-AML karyotypes were heterogeneous and were similar in distribution to those in HIV-negative AML. Among intensively treated patients, most achieved complete remission, but succumbed to infectious complications, mostly non-opportunistic, during consolidation therapy. Median survival for intensively-treated patients with CD4 counts ≤200×10 6 cells/L was 8.5 months, compared to 48 months for those with >200×10 6 CD4 cells/L (p=0.03). In contrast, AML karyotype did not predict survival (p=0.43), albeit with small numbers in each karyotype group. Thus, CD4 count is a strong predictor of short survival in HIV-AML patients regardless of karyotype. Studies evaluating innovative strategies for infection prophylaxis and for improving immune reconstitution are needed.

KW - Acquired immunodeficiency syndrome

KW - Acute myeloid leukemia

KW - Human immunodeficiency virus

KW - Risk assessment

UR - http://www.scopus.com/inward/record.url?scp=84859026010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859026010&partnerID=8YFLogxK

U2 - 10.3109/10428194.2011.624228

DO - 10.3109/10428194.2011.624228

M3 - Article

C2 - 21942284

AN - SCOPUS:84859026010

VL - 53

SP - 660

EP - 664

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 4

ER -